doi: 10.3389/fendo.2026.1822475 Received 03 March 2026 Revised 05 May 2026 Accepted 02 June 2026 Published 18 June 2026 Volume 17 - 2026 Edited by Carmine Bruno, Link Campus University, Italy Reviewed by Matej Rakusa, University Medical Centre Ljubljana, Slovenia Fredrik Tiberg, Camurus AB, Sweden Updates Copyright 2026 Dominikowski, Rko, Olejarz, Szczepanek-Parulska, Domin and Ruchaa
Clinical practice guideline exercise and lifestyle in chronic kidney disease
Its important to use these medications under appropriate medical supervision, especially considering the nuanced differences and potential for off-label application
Innovative Dual-Action Mechanism Tirzepatides unique combination of GLP-1 and GIP receptor agonism targets appetite regulation and glucose control more comprehensively
The Takeaway When it comes to fasting, I dont think we always need to be aiming for perfection
Description What is IGF-1 DES